Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIV5-based H5N1 vaccine
- Development stage
- Preclinical
- Lead developer
- CyanVac
- Modality
- Recombinant Proteins and Enzymes, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
A PIV5-based H5N1 vaccine is a recombinant live-attenuated viral vector vaccine that uses Parainfluenza Virus 5 (PIV5) to express the hemagglutinin (HA) gene from the highly pathogenic avian influenza virus subtype H5N1. The mechanism of action involves the delivery and expression of the influenza HA antigen by the PIV5 vector in host cells, inducing both humoral and cellular immune responses against HPAI H5N1. This approach has demonstrated sterilizing immunity in animal models with a single low-dose intranasal administration. The platform offers advantages such as high yield production in tissue culture and needle-free delivery. CyanVac is developing proprietary intranasal vaccines using this technology[1][3][4][6].
- Other names
- recombinant Parainfluenza Virus 5 expressing H5N1 hemagglutinin
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on PIV5-based H5N1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIV5-based H5N1 vaccine.